1Jemal A, Bray F,Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61:69-90.
2Archie V, Kauh J,Jones DV, et al. Gastric cancer: standards for the 21st century[J]. Crit Rev Oncol Hematol, 2006, 57: 123-131.
3Jadad AR,Moore RA,Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? [J]. Control Clin Trials, 1996,17:1-12.
4Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-l, an oral fluoropyrim- idine[J]. New Engl J Med, 2007,357:1810-1820.
5Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase Ⅲ trial comparing adjuvant chemothera- py with S-I versus surgery alone in stage Ⅱ or Ⅲ gastric canc er[J]. J Clin Oncol, 2011,29: 4387-4393.
6Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional flu- orouraci) in advanced gastric or gastroesophageal adenocarcino- ma study., the FLAGS trial[J]. J Clin Oncol, 2010,28: 1547- 1553.
7Kim GM,Jeung HC, Rha SY, et al. A randomized phase Ⅱ trial of S-l-oxaliplatin versus eapecitabine-oxaliplatin in ad- vanced gastric eancer[J]. Eur J Cancer, 2012,48:518-526.
8Sato A, Ito T, Tomita T, et alo Chemotherapy of gastric cancer-a review of clinical trials in Japan[J]. Gan To Kagaku Ryoho, 2002,29:1522-1531.
9Paotetti X, Oha K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: A meta-analysis [J]. JAMA, 2010, 303:1729-1737.
